Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Unmet needs for Kaposi sarcoma

Ramya Ramaswami • 31 May 2025
ASCO 2025
Sarcoma Pomalidomide

Ramya Ramaswami, MBBS, MPH, National Cancer Institute, Bethesda, MD, discusses areas of unmet need for patients with Kaposi sarcoma, noting significant gaps between therapy approvals – from early HIV epidemic treatments in the mid-90s to pomalidomide’s approval in 2020. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ramya Ramaswami

Assessing abemaciclib in HIV-associated & negative Kaposi sarcoma
3:55
Assessing abemaciclib in HIV-associated & negative Kaposi sarcoma
Ramya Ramaswami • 31 May 2025
Phase I trial of NT-I7, a long-acting IL-7, in Kaposi sarcoma
1:31
Phase I trial of NT-I7, a long-acting IL-7, in Kaposi sarcoma
Ramya Ramaswami • 31 May 2025

Related Videos

ctDNA monitoring for recurrence in bone and soft tissue sarcoma
0:58
ctDNA monitoring for recurrence in bone and soft tissue sarcoma
Maggie Zhou • 1 Jun 2026
ctDNA improves detection and prognostication of sarcoma recurrence
0:45
ctDNA improves detection and prognostication of sarcoma recurrence
Maggie Zhou • 1 Jun 2026
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
1:00
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
Maggie Zhou • 1 Jun 2026
Afami-cel T-cell therapy outcomes in advanced metastatic synovial sarcoma
1:52
Afami-cel T-cell therapy outcomes in advanced metastatic synovial sarcoma
Margaret von Mehren • 31 May 2026
The content of VJOncology is intended for healthcare professionals